Laboratory of Pharmaceutical Microbiology, Ghent University, Ottergemsesteenweg 460, 9000 Gent, Belgium.
Laboratory of Pharmaceutical Microbiology, Ghent University, Ottergemsesteenweg 460, 9000 Gent, Belgium.
Int J Antimicrob Agents. 2017 Mar;49(3):315-320. doi: 10.1016/j.ijantimicag.2016.11.023. Epub 2017 Jan 31.
Staphylococcus aureus biofilms are involved in a wide range of infections that are extremely difficult to treat with conventional antibiotic therapy. We aimed to identify potentiators of antibiotics against mature biofilms of S. aureus Mu50, a methicillin-resistant and vancomycin-intermediate-resistant strain. Over 700 off-patent drugs from a repurposing library were screened in combination with vancomycin in a microtitre plate (MTP)-based biofilm model system. This led to the identification of 25 hit compounds, including four phenothiazines among which thioridazine was the most potent. Their activity was evaluated in combination with other antibiotics both against planktonic and biofilm-grown S. aureus cells. The most promising combinations were subsequently tested in an in vitro chronic wound biofilm infection model. Although no synergistic activity was observed against planktonic cells, thioridazine potentiated the activity of tobramycin, linezolid and flucloxacillin against S. aureus biofilm cells. However, this effect was only observed in a general biofilm model and not in a chronic wound model of biofilm infection. Several drug compounds were identified that potentiated the activity of vancomycin against biofilms formed in a MTP-based biofilm model. A selected hit compound lost its potentiating activity in a model that mimics specific aspects of wound biofilms. This study provides a platform for discovering and evaluating potentiators against bacterial biofilms and highlights the necessity of using relevant in vitro biofilm model systems.
金黄色葡萄球菌生物膜参与了广泛的感染,这些感染用传统的抗生素治疗极其困难。我们旨在确定金黄色葡萄球菌 Mu50 成熟生物膜的抗生素增效剂,这是一种耐甲氧西林和中间耐万古霉素的菌株。在基于微量滴定板(MTP)的生物膜模型系统中,我们筛选了来自再利用库的 700 多种专利外药物与万古霉素联合使用。这导致鉴定了 25 个命中化合物,其中包括四个吩噻嗪,其中噻吨嗪最有效。评估了它们与其他抗生素联合使用对浮游生物和生物膜生长的金黄色葡萄球菌细胞的活性。随后,在体外慢性伤口生物膜感染模型中测试了最有前途的组合。虽然没有观察到对浮游细胞的协同活性,但噻吨嗪增强了妥布霉素、利奈唑胺和氟氯西林对金黄色葡萄球菌生物膜细胞的活性。然而,这种作用仅在一般生物膜模型中观察到,而在慢性伤口生物膜感染模型中未观察到。鉴定出几种药物化合物,它们增强了 MTP 基于生物膜模型中形成的生物膜对万古霉素的活性。一种选定的命中化合物在模拟伤口生物膜特定方面的模型中失去了其增效活性。这项研究为发现和评估针对细菌生物膜的增效剂提供了一个平台,并强调了使用相关体外生物膜模型系统的必要性。